Overview
Non-Inferiority Study, Post-Market Clinical Investigation with a Device, Single-Blind Randomized Controlled Trial in a Cohort of Patients Diagnosed with Multiple Sclerosis (MS).
The aim of the study is to assess whether a computer-based cognitive treatment delivered via telerehabilitation produces effects from T0 to T1 that are not inferior to those of an in-person treatment on sustained attention in a cohort of patients with MS.
The secondary objective is to evaluate the effects of telerehabilitation compared to the same treatment delivered in person on attentional shifting, memory, executive functions, and daily functioning (including cognitive fatigue, quality of life, and mood) in patients with MS.
Eligibility
Inclusion Criteria:
- Diagnosis of relapsing-remitting multiple sclerosis (RRMS), or primary progressive (PPMS) or secondary progressive (SPMS), defined by at least 3-6 months.
- Age between 18 and 65 years.
- Expanded Disability Status Scale (EDSS) between 3 and 5 to include patients with overall neurological disability from mild to moderate.
- Presence of one or more of the following cognitive disorders (reported by the patient and subsequently confirmed through the Oxford Cognitive Screen-OCS):
- Memory disorders
- Attention disorders
- Executive function disorders
- Availability of internet at the patient's home necessary for the tele-rehabilitation procedures.
- Adequate visual and auditory abilities to use the rehabilitation device.
Exclusion Criteria:
- Presence of other neurological conditions;
- Psychiatric disorders in medical history;
- Alcohol and/or drug abuse;
- Presence of uncorrected severe visual deficits.